ARDS is a severe, life-threatening form of acute respiratory failure characterized by widespread inflammatory lung injury causing massive fluid accumulation in the alveoli, catastrophic collapse of gas exchange, and refractory hypoxemia that does not readily respond to supplemental oxygen alone.
It represents the most devastating end of the hypoxemic respiratory failure spectrum — the point at which the lungs have been so severely injured that they can no longer sustain life without aggressive mechanical support.
Formal Definition — The Berlin Criteria (2012)
ARDS is officially diagnosed when all four of the following are present:
| Criterion | Requirement |
|---|---|
| Timing | Acute onset within 1 week of a known clinical insult or new/worsening respiratory symptoms |
| Chest Imaging | Bilateral opacities on chest X-ray or CT — not fully explained by effusions, collapse, or nodules |
| Origin of Edema | Respiratory failure not fully explained by cardiac failure or fluid overload (echo may be needed to exclude cardiogenic pulmonary edema) |
| Oxygenation | PaO₂/FiO₂ ratio (P/F ratio) < 300 on PEEP or CPAP ≥ 5 cmH₂O |
Severity Classification by P/F Ratio
The PaO₂/FiO₂ ratio (P/F ratio) is the cornerstone of ARDS severity grading — it measures how efficiently the lungs are transferring oxygen relative to what is being delivered:
| Severity | P/F Ratio | Mortality |
|---|---|---|
| Mild ARDS | 200 – 300 mmHg | ~27% |
| Moderate ARDS | 100 – 200 mmHg | ~32% |
| Severe ARDS | < 100 mmHg | 45 – 60%+ |
A normal P/F ratio is 400–500 mmHg. An ARDS patient with a P/F of 80 is receiving near-maximal oxygen yet their blood oxygen remains critically low — illustrating how devastatingly impaired gas exchange has become.
Pathophysiology — What Happens to the Lung
ARDS progresses through three overlapping phases:
Phase 1 — Exudative Phase (Days 1–7)
The acute injury phase:
- A triggering insult (infection, trauma, aspiration, etc.) activates a massive systemic inflammatory response
- Neutrophils, macrophages, and inflammatory cytokines (IL-1, IL-6, TNF-α) flood the lungs
- The alveolar-capillary barrier — normally a tight, selective membrane — is destroyed
- Protein-rich fluid, red blood cells, and debris pour into the alveoli (non-cardiogenic pulmonary edema)
- Surfactant is destroyed → alveoli lose surface tension → diffuse alveolar collapse
- Hyaline membranes form — glassy deposits lining the alveolar walls, hallmark of ARDS on autopsy
- Result: Massive shunting, profound hypoxemia, stiff non-compliant lungs
Phase 2 — Proliferative Phase (Days 7–21)
The repair and remodeling phase:
- Type II pneumocytes proliferate attempting to resurface damaged alveoli
- Inflammation begins to resolve in survivors
- Early fibroblast infiltration begins — the lung starts laying down collagen
- Lung compliance slowly improves
- Some patients recover here; others progress to fibrosis
Phase 3 — Fibrotic Phase (> 3 weeks)
In severe or prolonged cases:
- Progressive pulmonary fibrosis — permanent scarring replaces normal lung tissue
- Lung architecture is irreversibly distorted
- Cysts and bullae form — creating high risk of pneumothorax
- Chronic hypoxemia and pulmonary hypertension may persist
- This phase is associated with the worst long-term outcomes
Causes and Triggers
ARDS is triggered by both direct lung injuries and indirect systemic insults:
Direct Lung Injury (Pulmonary ARDS):
- Pneumonia — most common cause (bacterial, viral, fungal)
- Aspiration of gastric contents
- Pulmonary contusion (chest trauma)
- Inhalation injury — smoke, toxic gases, chemical fumes
- Near-drowning
- Mechanical ventilation injury (ventilator-induced lung injury — VILI)
Indirect / Extrapulmonary Triggers:
- Sepsis — the single most common cause overall (accounting for ~40% of ARDS cases)
- Severe trauma with shock
- Pancreatitis (severe acute)
- Burns (extensive)
- Massive blood transfusion — TRALI (Transfusion-Related Acute Lung Injury)
- Drug overdose — heroin, salicylates, certain chemotherapy agents
- Disseminated Intravascular Coagulation (DIC)
- Cardiopulmonary bypass
The “Baby Lung” Concept
One of the most important concepts in understanding ARDS:
- In ARDS, CT imaging reveals that lung injury is heterogeneous — not uniform
- Three distinct zones coexist simultaneously:
- Collapsed/consolidated zones — typically dependent (gravity-dependent lower/posterior regions); fluid-filled, non-aerated, contributing to shunt
- Recruitable zones — potentially reopenable with pressure
- Normal zones — relatively preserved; typically non-dependent (upper/anterior regions)
- The “normal” zone behaves like a small baby’s lung in terms of volume — roughly 1/3 the size of a normal adult lung
- This means ventilating an ARDS patient with normal adult tidal volumes is catastrophic — it overdistends the small remaining functional lung → causing additional injury (volutrauma/barotrauma)
- This insight is the scientific foundation of lung-protective ventilation
Arterial Blood Gas Profile
| Value | Normal | Mild ARDS | Severe ARDS |
|---|---|---|---|
| pH | 7.35 – 7.45 | 7.40–7.50 (alkalotic) | < 7.30 (acidotic — exhaustion) |
| PaO₂ | 80–100 mmHg | 60–80 mmHg | < 55 mmHg |
| PaCO₂ | 35–45 mmHg | Low–normal | Elevated (fatigue/hypoventilation) |
| HCO₃⁻ | 22–26 mEq/L | Normal | Low (metabolic acidosis overlay) |
| P/F Ratio | 400–500 | 200–300 | < 100 |
| SpO₂ | 95–100% | 88–92% | < 85% despite high FiO₂ |
Clinical Presentation
Onset:
- Typically develops 12–48 hours after the triggering insult (occasionally up to 5 days)
- Rarely presents as the initial problem — almost always follows a known injury or illness
Symptoms:
Respiratory:
- Rapidly progressive, severe shortness of breath
- Tachypnea (respiratory rate often > 30 breaths/min)
- Extreme air hunger and respiratory distress
- Accessory muscle use — neck, shoulders, abdomen working visibly
- Intercostal and supraclavicular retractions
- Cyanosis — lips, tongue, fingernails (central cyanosis)
- Diffuse crackles bilaterally on auscultation
Systemic:
- Profound anxiety and agitation (from hypoxia)
- Diaphoresis
- Tachycardia
- Fever (if infectious trigger)
- Hypotension (especially if sepsis-driven)
- Altered mental status progressing to obtundation
Ominous Signs:
- Paradoxical calm — patient stops fighting → respiratory muscle exhaustion → imminent arrest
- Bradycardia — late pre-arrest sign
- Loss of consciousness
Chest Imaging
Chest X-Ray:
- Bilateral, diffuse, fluffy opacities (whiteout pattern in severe cases)
- Distinguishable from cardiogenic pulmonary edema by:
- No cardiomegaly
- No vascular redistribution (cephalization)
- No pleural effusions (or minimal)
- No Kerley B lines
- Infiltrates are peripheral and patchy rather than central/perihilar
CT Chest:
- Reveals the heterogeneous nature of ARDS injury — not visible on plain film
- Shows:
- Dependent consolidation (posterior/lower zones — heavy, fluid-filled lung sinking)
- Ground-glass opacities in mid-zones
- Relatively spared anterior zones
- Air bronchograms within consolidated areas
- Possible pneumothorax from barotrauma
Treatment — Comprehensive
1. Mechanical Ventilation — The Cornerstone
Lung-Protective Ventilation (LPV) — the single most important intervention proven to reduce ARDS mortality:
- Low tidal volume: 6 mL/kg ideal body weight (not actual weight)
- Prevents volutrauma — overdistension of the baby lung
- The ARDSNet trial (2000) demonstrated a 22% relative mortality reduction with this strategy
- Plateau pressure ≤ 30 cmH₂O — prevents barotrauma
- Driving pressure ≤ 15 cmH₂O (plateau pressure minus PEEP) — emerging as the most important pressure target
- PEEP (Positive End-Expiratory Pressure): Keeps alveoli open at end-expiration, prevents cyclic collapse-reopening injury (atelectrauma)
- Higher PEEP (10–20 cmH₂O) in severe ARDS to recruit collapsed alveoli
- Must be balanced against risk of overdistension and hemodynamic compromise
- FiO₂: Titrate to achieve SpO₂ 88–95% — avoid both hypoxia and oxygen toxicity
- Permissive Hypercapnia: Allow CO₂ to rise (PaCO₂ 45–60 mmHg) rather than increase tidal volumes — accepted tradeoff in lung protection
2. Prone Positioning — Proven Mortality Reducer
- Patient placed face-down for 16+ hours per day
- Dramatically redistributes perfusion to better-ventilated anterior lung zones
- Recruits collapsed posterior (dependent) zones
- Reduces V/Q mismatch and shunting
- The PROSEVA trial showed prone positioning reduced 28-day mortality from 32.8% to 16% in severe ARDS (P/F < 150)
- Now standard of care for moderate-severe ARDS
- Requires experienced team — risks include endotracheal tube dislodgement, pressure ulcers, hemodynamic instability
3. Fluid Management — Conservative Strategy
- Conservative fluid strategy after initial resuscitation is preferred
- Excess fluid worsens pulmonary edema and alveolar flooding
- FACTT Trial showed conservative fluid management (guided by CVP targets) improved lung function and reduced ventilator days
- Diuretics used to achieve net-negative fluid balance once hemodynamically stable
- Balance: enough fluid to maintain perfusion, not so much as to drown the lungs further
4. Neuromuscular Blockade (NMB)
- Cisatracurium infusion (48–72 hours) in moderate-severe ARDS
- Eliminates patient-ventilator dyssynchrony
- Reduces spontaneous breathing effort that can worsen lung injury (P-SILI — patient self-inflicted lung injury)
- ACURASYS trial initially showed mortality benefit; ROSE trial questioned it — currently used selectively in severe dyssynchrony or refractory hypoxemia
5. Corticosteroids
- Methylprednisolone — used in select cases to reduce pulmonary inflammation
- Evidence is mixed — most benefit seen when given in the proliferative phase (after day 7) or in COVID-19 ARDS (dexamethasone — RECOVERY trial showed clear mortality benefit)
- Risk: immunosuppression, secondary infections, hyperglycemia, myopathy
6. Rescue Therapies for Refractory Hypoxemia
When standard ventilation fails to maintain acceptable oxygenation:
Inhaled Vasodilators:
- Inhaled Nitric Oxide (iNO) — selectively dilates pulmonary vessels in ventilated zones → redirects blood flow away from shunt units → improves V/Q matching
- Inhaled Prostacyclin (Epoprostenol) — similar mechanism, less expensive
- Both improve oxygenation short-term but have not been proven to reduce mortality
- Used as bridge to other therapies or organ recovery
Recruitment Maneuvers:
- Brief application of high sustained airway pressure to open collapsed alveoli
- Controversial — the ART trial showed harm with aggressive recruitment; used cautiously and selectively
High-Frequency Oscillatory Ventilation (HFOV):
- Delivers very small tidal volumes at high frequency (3–15 Hz)
- Theoretically ideal for lung protection
- Trials (OSCILLATE, OSCAR) showed no mortality benefit and possible harm
- Largely abandoned except in pediatric ARDS
ECMO — Extracorporeal Membrane Oxygenation:
- The ultimate rescue therapy — the lungs are bypassed entirely
- Blood is removed from the body, oxygenated by an artificial membrane, CO₂ removed, and returned
- Veno-venous ECMO (VV-ECMO) — for respiratory failure without cardiac failure
- Veno-arterial ECMO (VA-ECMO) — when cardiac failure coexists
- CESAR trial and EOLIA trial support ECMO referral in severe refractory ARDS
- Requires specialized ECMO center; significant complications (bleeding, thrombosis, infection)
- Used when P/F ratio < 80 despite optimal ventilator management
7. Treat the Underlying Cause
ARDS will not resolve without addressing the precipitating insult:
- Sepsis → early antibiotics, source control, vasopressors (norepinephrine), sepsis bundles
- Pneumonia → pathogen-targeted antibiotics/antivirals
- Aspiration → antibiotics, bronchoscopy for airway clearance
- Pancreatitis → supportive care, nutrition
- TRALI → stop the offending blood product, supportive care
- COVID-19 → dexamethasone, antivirals (remdesivir), anticoagulation
8. Supportive ICU Care
- Deep Vein Thrombosis (DVT) prophylaxis — pharmacologic (heparin) and mechanical (sequential compression devices)
- Stress ulcer prophylaxis — proton pump inhibitors
- Early enteral nutrition — nasogastric or post-pyloric feeding; prevents gut translocation, maintains mucosal integrity
- Glycemic control — target blood glucose 140–180 mg/dL
- Sedation protocols — lightest effective sedation; daily sedation interruption (“awakening trials”)
- Early physical therapy — even on the ventilator when feasible; prevents ICU-acquired weakness
Complications
During ICU Stay:
- Ventilator-Associated Pneumonia (VAP) — new infection superimposed on injured lungs
- Barotrauma / Volutrauma — pneumothorax, pneumomediastinum from ventilator pressure
- Pulmonary hypertension — from hypoxic vasoconstriction and vascular remodeling
- Right heart failure (Cor Pulmonale) — from elevated pulmonary pressures
- Multi-Organ Dysfunction Syndrome (MODS) — kidneys, liver, brain, gut fail alongside the lungs
- ICU-acquired weakness — profound muscle wasting from immobility, sedation, NMB
- Delirium — nearly universal in ventilated ICU patients; associated with worse outcomes
Long-Term (Post-ARDS Syndrome):
- Pulmonary fibrosis — permanent scarring; chronic dyspnea and exercise limitation
- Neurocognitive impairment — memory loss, executive dysfunction, PTSD
- Psychiatric sequelae — depression, anxiety, PTSD (40–60% of ARDS survivors)
- Physical deconditioning — muscle weakness, fatigue lasting months to years
- Reduced quality of life — most ARDS survivors report significant functional limitations at 1 year
Prognosis
| Factor | Better Prognosis | Worse Prognosis |
|---|---|---|
| Age | Younger | Older (> 65) |
| P/F Ratio | > 200 | < 100 |
| Trigger | Pneumonia, aspiration | Sepsis, MODS |
| Comorbidities | Few | Multiple (liver failure, cancer, immunocompromise) |
| Response to Prone | Rapid PaO₂ improvement | Non-responder |
| Lung Compliance | Relatively preserved | Severely reduced |
Overall Mortality: 26–45% in modern ICUs — improved significantly from the 60–70% mortality seen before lung-protective ventilation became standard.
Survivors often face a prolonged recovery — many require weeks of mechanical ventilation, months of rehabilitation, and years to approach baseline function.
Summary — ARDS in One Framework
TRIGGER (Sepsis, Pneumonia, Trauma, Aspiration)
↓
Massive Inflammatory Cascade
↓
Alveolar-Capillary Barrier Destroyed
↓
Protein-Rich Fluid Floods Alveoli + Surfactant Lost
↓
Diffuse Alveolar Collapse → Massive Shunting
↓
Refractory Hypoxemia (P/F < 300)
↓
Stiff, Non-Compliant Lungs ("Wet Concrete")
↓
ARDS — Managed with Lung-Protective Ventilation,
Prone Positioning, Treat Underlying Cause,
± ECMO if Refractory
↓
Recovery (weeks–months) OR Fibrosis OR Death
ARDS remains one of the most challenging syndromes in critical care medicine — not because the diagnosis is complex, but because the lungs must be kept alive with the very machine (the ventilator) that can simultaneously destroy them if used incorrectly. The art of ARDS management is protecting what remains while the underlying cause is conquered.